Louis Lantier, Agathe Poupée-Beaugé, Anne di Tommaso, Céline Ducournau, Mathieu Epardaud, Zineb Lakhrif, Stéphanie Germon, Françoise Debierre-Grockiego, Marie-Noëlle Mévélec, Arthur Battistoni, Loïs Coënon, Nora Deluce-Kakwata-Nkor, Florence Velge-Roussel, Céline Beauvillain, Thomas Baranek, Gordon Scott Lee, Thibault Kervarrec, Antoine Touzé, Nathalie Moiré, Isabelle Dimier-Poisson
BACKGROUND: Microorganisms that can be used for their lytic activity against tumor cells as well as inducing or reactivating antitumor immune responses are a relevant part of the available immunotherapy strategies. Viruses, bacteria and even protozoa have been largely explored with success as effective human antitumor agents. To date, only one oncolytic virus-T-VEC-has been approved by the US Food and Drug Administration for use in biological cancer therapy in clinical trials. The goal of our study is to evaluate the potential of a livestock pathogen, the protozoan Neospora caninum, non-pathogenic in humans, as an effective and safe antitumorous agent...
November 2020: Journal for Immunotherapy of Cancer